-+ 0.00%
-+ 0.00%
-+ 0.00%

LIVSAYIS™ (CEMDISIRAN) APPROVED BY THE FDA AS FIRST AND ONLY SIRNA THERAPY IN GENERALIZED MYASTHENIA GRAVIS AND ONLY TREATMENT WITH FOUR-TIMES-A-YEAR SUBCUTANEOUS DOSING

Reuters·11/18/2026 23:03:43

Please log in to view news